Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Non-Current Liabilities: 2014-2025

Historic Other Non-Current Liabilities for CytomX Therapeutics (CTMX) over the last 7 years, with Sep 2025 value amounting to $4.3 million.

  • CytomX Therapeutics' Other Non-Current Liabilities rose 6.07% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 6.07%. This contributed to the annual value of $4.1 million for FY2024, which is 5.70% up from last year.
  • Per CytomX Therapeutics' latest filing, its Other Non-Current Liabilities stood at $4.3 million for Q3 2025, which was up 1.37% from $4.2 million recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Other Non-Current Liabilities high stood at $4.3 million for Q3 2025, and its period low was $216,000 during Q2 2023.
  • Its 3-year average for Other Non-Current Liabilities is $3.6 million, with a median of $4.0 million in 2024.
  • Data for CytomX Therapeutics' Other Non-Current Liabilities shows a peak YoY skyrocketed of 1,748.61% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows CytomX Therapeutics' Other Non-Current Liabilities stood at $3.9 million in 2023, then grew by 5.70% to $4.1 million in 2024, then rose by 6.07% to $4.3 million in 2025.
  • Its Other Non-Current Liabilities stands at $4.3 million for Q3 2025, versus $4.2 million for Q2 2025 and $4.2 million for Q1 2025.